Amy Van Buskirk – General Manager, Roche Sweden
Amy Van Buskirk, general manager of Roche Sweden, discusses the role Roche plays in the Swedish healthcare system, how Sweden is becoming an innovation leader once more as well as…
Amy Van Buskirk, general manager of Roche Sweden, discusses the role Roche plays in the Swedish healthcare system, how Sweden is becoming an innovation leader once more as well as…
Dr. Olsson Birgersson, Medical Director of Roche Sweden argues the importance of developing clinical research within Sweden, why the Swedish healthcare system is no longer the forerunner in Europe that…
The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis…
After working at Ipsen for seven years, of which you have spent four as the head of the Nordics, what would you say have been the company’s main milestones in…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing Manager for Europe at…
“The Nordic region—the ‘quiet North’ as it could have been called—counterbalances the turbulence in Southern Europe,” says Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of…
Could you begin by introducing Diamyd Medical and therapeutic focus to those of our international readership that are not yet familiar with your name? Diamyd was recently listed on Nasdaq’s…
Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary…
As the blockbuster sales model fades, the rush is on for a new formula for growth, termed ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from…
You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing…
Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was…
Last year, Boston Scientific took important steps to stabilise and strengthen its core businesses. Could you develop on the development trajectory of Boston Scientific in the Nordic region so far?…
See our Cookie Privacy Policy Here
